A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD)
Phase of Trial: Phase II/III
Latest Information Update: 18 Dec 2018
At a glance
- Drugs CNP 520 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms Generation S2
- Sponsors Novartis Pharmaceuticals
- 16 Oct 2018 Planned End Date changed from 30 Aug 2024 to 31 Mar 2025.
- 31 Aug 2018 Biomarkers information updated
- 02 Apr 2018 Planned End Date changed from 31 Aug 2024 to 30 Aug 2024.